Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,232 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06206174 | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 30 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06345365 | MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | recruiting | Phase 3 | 154 | Zhongnan HospitalOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| Chronic Myeloid Leukemia (CML) Real-Life Database |
| recruiting |
| — |
| 3,500 |
| University Hospital, Clermont-FerrandOTHER |
| 1 |
| Apr 9, 2024 |
| clinicaltrials |
| NCT06250959 | RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.(BEAT-ALL-2024) | recruiting | Phase 2 | 124 | Chen SuningOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT05477264 | Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type | recruiting | Phase 2 | 38 | Won Seog KimOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06339255 | Italian Observational Study on CAR-T Therapy for Lymphoma(CART-SIE) | recruiting | — | 5,300 | Paolo CorradiniOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06329999 | A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML | recruiting | N/A | 78 | Ruijin HospitalOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06321289 | Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06328179 | Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. | recruiting | N/A | 34 | Huai'an First People's HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06270667 | Effects of Exercise Training in Survivors of Lymphoma(LYMfit) | recruiting | N/A | 280 | Norwegian School of Sport SciencesOTHER | 2 | Mar 22, 2024 | clinicaltrials |
| NCT04243785 | A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | recruiting | Phase 1 | 80 | Edgewood Oncology Inc.INDUSTRY | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06232096 | A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. | recruiting | Phase 1 / Phase 2 | 154 | Beijing Mabworks Biotech Co., Ltd.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03131531 | Bergamo Lymphoid Cancer Registry | recruiting | — | 6,000 | A.O. Ospedale Papa Giovanni XXIIIOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06046313 | Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS | recruiting | Phase 2 | 120 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06279026 | UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | N/A | 15 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06228963 | Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma | recruiting | Phase 2 | 160 | Fudan UniversityOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06263530 | Prognostic Significance of ctDNA in HL | recruiting | — | 500 | Interni hematologicka klinika FNKVNETWORK | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06256627 | The Maintenance Treatment of "ITIVA" in AML Patients | recruiting | N/A | 130 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06250595 | European Rare Blood Disorders Platform (ENROL)(ENROL) | recruiting | — | 37,090 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06246162 | Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06237192 | MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients | recruiting | N/A | 200 | National Research Center for Hematology, RussiaNETWORK | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05243212 | Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 75 | Sheba Medical CenterOTHER_GOV | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05695638 | Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment | recruiting | — | 3,000 | Morten LadekarlOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06225856 | An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies | recruiting | Phase 1 | 96 | Shanghai Yuyao Biotech Co., Ltd.INDUSTRY | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06232694 | Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML | recruiting | N/A | 54 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05379738 | Impact of Adapted Physical Activity on Patient's Recovery Following Allogeneic Stem Cell Transplantation for Hematological Malignancy(APALLO) | recruiting | N/A | 75 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06190067 | Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma | recruiting | Phase 2 | 40 | Navy General Hospital, BeijingOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06220487 | A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL(ABC) | recruiting | Phase 2 | 67 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06211166 | Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction | recruiting | — | 300 | Peking University People's HospitalOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT01281735 | International Chronic Myeloid Leukemia Pediatric Study(ICMLPed) | recruiting | — | 750 | Poitiers University HospitalOTHER | 20 | Jan 17, 2024 | clinicaltrials |
| NCT06203652 | The Pathogenesis and Prognostic Factors of Lymphoma | recruiting | — | 2,000 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT04897490 | RWE of 1st Line Treatment With ATO/ATRA for Adult APL | recruiting | — | 50 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05127148 | RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALL | recruiting | — | 100 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05246345 | Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia(RAVEN) | recruiting | — | 50 | University Hospital, Clermont-FerrandOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06196255 | Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05675813 | Genotype-guided Treatment in Newly Diagnosed PTCL(THEORY) | recruiting | Phase 1 / Phase 2 | 264 | Ruijin HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05833763 | A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.(GOlDiLOX) | recruiting | Phase 2 | 42 | Australasian Leukaemia and Lymphoma GroupOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT06188676 | Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL | recruiting | Phase 3 | 100 | National Research Center for Hematology, RussiaNETWORK | 1 | Jan 3, 2024 | clinicaltrials |
| NCT05839392 | Novel Approaches to Target MECOM/EVI1 in AML | recruiting | N/A | 24 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT06180174 | Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma | recruiting | Phase 1 | 24 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Dec 28, 2023 | clinicaltrials |
| NCT05245487 | Danish Elder Lymphoma Patient Hematopoietic Investigation(DELPHI) | recruiting | — | 300 | Rigshospitalet, DenmarkOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT06176729 | Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients | recruiting | Phase 2 | 30 | Yan Zhang, MDOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06158269 | DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma | recruiting | Phase 2 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT05788679 | A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS | recruiting | Phase 2 | 200 | Karolinska University HospitalOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT06155188 | Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia | recruiting | N/A | 60 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT05694312 | Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL | recruiting | Phase 2 | 45 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT04263857 | Register of Blood Stem Cell Transplantation(REBB3M) | recruiting | — | 5,000 | Technical University of MunichOTHER | 1 | Nov 24, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 10, 2024source: clinicaltrials